The FDA has approved the use of enzalutamide (Xtandi, Pfizer/Astellas) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
“The research supporting the FDA approval and updated treatment guidelines pro-vide physicians and patients with compelling evidence to consider enzalutamide as a treatment option for men with this disease,” noted investigator Andrew Armstrong, MD, the director of research at Duke Cancer Institute’s Center for